Research Activities
Our programs, projects and other research activities tackle ongoing challenges in translational research so that new treatments and other health solutions can reach people faster.
Research Activities at NCATS
Through our research activities, we overcome roadblocks that slow progress on developing treatments for many different diseases and that can lead to inequities in clinical outcomes. Explore the range of initiatives we support at NCATS and beyond.
OpenData Portal
Our OpenData Portal is an open and accessible platform for sharing COVID-19-related drug repurposing data and experiments involving approved drugs.
Platform Vector Gene Therapy (PaVe-GT)
Our pilot project is testing the feasibility of increasing the efficiency of gene therapy clinical trials by using the same gene delivery system and manufacturing methods for multiple gene therapies.
Rare Diseases Clinical Research Network (RDCRN)
We oversee this NIH-wide grant program that supports medical research on over 200 rare diseases through clinical studies, including collaborations, study enrollment and data sharing.
Somatic Cell Genome Editing
We help lead this NIH Common Fund program that aims to create and make available high-quality tools for safe and effective genome editing to decrease the time and cost of creating new therapies.
Stem Cell Translation Laboratory (SCTL)
Our experts develop methods and standards to use stem cell technology (using cells derived from skin or blood) to advance treatment approaches.
The Helping to End Addiction Long-termĀ® Initiative, or NIH HEAL InitiativeĀ®
As part of the NIH HEAL Initiative, we are applying our translational science approaches to accelerate the development of new treatments for opioid misuse, addiction and pain management.
Therapeutics for Rare and Neglected Diseases (TRND)
Our experts help move new treatments for rare and neglected diseases through the later stages of drug development by collaborating with external scientists and companies.
Tissue Chip for Drug Screening
This program funds the development and testing of models built from human cells for predicting drug safety and toxicity before clinical testing in people.